Cancer Clinical Trials

10,204 recruitingLast updated: May 28, 2026

There are 10,204 actively recruiting cancer clinical trials across 129 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Houston, Texas, United States, Shanghai, Shanghai Municipality, China. Updated daily from ClinicalTrials.gov.


Cancer Trials at a Glance

10,204 actively recruiting trials for cancer are listed on ClinicalTrialsFinder across 6 cities in 129 countries. The largest study group is Phase 2 with 2,849 trials, with the heaviest enrollment activity in New York, Houston, and Shanghai. Lead sponsors running cancer studies include Fudan University, M.D. Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center.

Treatments under study

About Cancer Clinical Trials

Looking for clinical trials for Cancer? There are currently 901 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 10,204 trials

Recruiting
Phase 1Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 3

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled537 locationsNCT06058377
Recruiting
Phase 2Phase 3

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Non-small Cell Lung Cancer
Bristol-Myers Squibb500 enrolled186 locationsNCT07100080
Recruiting

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Solid TumorOther Solid TumorsVery Rare Tumors+2 more
National Cancer Institute (NCI)4,000 enrolled1 locationNCT07489378
Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 1

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab

Unresectable Advanced or Metastatic Solid Cancer
Boehringer Ingelheim60 enrolled9 locationsNCT07607678
Recruiting
Phase 3

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

Locally Advanced Cervical Cancer
AstraZeneca800 enrolled204 locationsNCT06079671
Recruiting
Phase 1

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

Advanced Relapsed or Refractory Germ Cell TumoursAdvanced Relapsed or Refractory Endometrial CancerAdvanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim187 enrolled13 locationsNCT07306559
Recruiting
Phase 2

Pan Tumor Rollover Study

Cancer
Bristol-Myers Squibb1,500 enrolled399 locationsNCT03899155
Recruiting
Phase 3

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma+3 more
National Cancer Institute (NCI)1,210 enrolled1151 locationsNCT04267848
Recruiting
Phase 1Phase 2

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled8 locationsNCT07288359
Recruiting
Phase 1

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Metastatic Breast CancerHER2-negative Breast CancerAdvanced Solid Tumor+6 more
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 1Phase 2

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Novartis Pharmaceuticals80 enrolled2 locationsNCT07564401
Recruiting

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

Non-small Cell Lung Cancer
AstraZeneca500 enrolled26 locationsNCT06068049
Recruiting
Phase 1Phase 2

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Brain CancerGBMGlioma+12 more
National Institute of Neurological Disorders and Stroke (NINDS)40 enrolled1 locationNCT07416188
Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled8 locationsNCT07326566
Recruiting
Not Applicable

A Study of Time-Restricted Eating in Childhood Cancer Survivors

Childhood Cancer Survivors
Memorial Sloan Kettering Cancer Center300 enrolled4 locationsNCT07009288
Recruiting
Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled324 locationsNCT06136650
Recruiting
Phase 1Phase 2

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Breast Cancer
Novartis Pharmaceuticals58 enrolled33 locationsNCT06247995
Recruiting
Phase 2

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer
AstraZeneca278 enrolled83 locationsNCT07098338